Efficacy and Safety of Teneligliptin in Combination With Metformin in Chinese Patients With Type 2 Diabetes Mellitus
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 247 participants.
Also called NCT02924064
- Study
- In this atlas
Overview
- Design
- Interventional study; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 247 participants
- Sponsor
- Registry
-
NCT02924064
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- Not reported
- Results first posted
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT02924064. Quadruple masking; primary purpose treatment. Start 2016-09 (registry gives no type); primary completion 2018-09-25 (actual). Results posted on 2022-01-28.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Teneligliptin in Combination With Metformin in Chinese Patients With Type 2 Diabetes Mellitus
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Teneligliptin 20mg
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Metformin ≥ 1000 mg
- Lead sponsor
- Tanabe Pharma Corporation
Record details
- Record id
cardio:ct-nct02924064- Content hash
22d64ce3abd9ede8d173b1786f6cd2ce5e3892741184c095da270582889851a7